Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2009. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific director transaction and does not contain financial statements or performance metrics.
Material Changes
The only material change disclosed is a transaction by a director:
- Director: Mr. A P Witty
- Action: Purchase of 8,166 Ordinary shares
- Price: £12.16 per share
- Date: November 4, 2009
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of a director's share purchase in accordance with Disclosure Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total shareholding of Mr. A P Witty following this purchase to assess alignment with company performance.
- Confirm the market price of GSK shares on November 4, 2009, to contextualize the £12.16 purchase price.
- Review subsequent filings for any additional director transactions or changes in ownership structure.